Dermata Therapeutics, Inc. (DRMA) Financial Statements (2024 and earlier)

Company Profile

Business Address 3525 DEL MAR HEIGHTS RD., #322
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments8,438,5308,766,7596,241,2948,066,82210,627,8958,190,958
Cash and cash equivalents8,438,5308,766,7596,241,2948,066,82210,627,8958,190,958
Total current assets:8,438,5308,766,7596,241,2948,066,82210,627,8958,190,958
Noncurrent Assets
Other undisclosed assets274,351528,346703,194908,067398,543853,057
TOTAL ASSETS:8,712,8819,295,1056,944,4888,974,88911,026,4389,044,015
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities682,8621,207,035922,6341,504,3221,366,4681,191,496
Accounts payable437,778492,871496,702483,741608,811662,230
Accrued liabilities245,084714,164425,9321,020,581757,657529,266
Total current liabilities:682,8621,207,035922,6341,504,3221,366,4681,191,496
Noncurrent Liabilities
Total liabilities:682,8621,207,035922,6341,504,3221,366,4681,191,496
Equity
Equity, attributable to parent8,030,0198,088,0706,021,8547,470,5679,659,9707,852,519
Common stock3192391,2321,2101,010833
Additional paid in capital57,564,39455,921,16151,613,81051,392,94251,157,95946,620,112
Accumulated deficit(49,534,694)(47,833,330)(45,593,188)(43,923,585)(41,498,999)(38,768,426)
Total equity:8,030,0198,088,0706,021,8547,470,5679,659,9707,852,519
TOTAL LIABILITIES AND EQUITY:8,712,8819,295,1056,944,4888,974,88911,026,4389,044,015

Income Statement (P&L) (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Operating expenses(1,732,414)(2,277,682)(1,711,689)(2,446,072)(2,730,573)(2,786,152)
Operating loss:(1,732,414)(2,277,682)(1,711,689)(2,446,072)(2,730,573)(2,786,152)
Interest and debt expense      (180,434)
Loss from continuing operations:(1,732,414)(2,277,682)(1,711,689)(2,446,072)(2,730,573)(2,966,586)
Loss before gain (loss) on sale of properties:(2,446,072)(2,730,573)(2,966,586)
Other undisclosed net income  4,517,824   180,435
Net income (loss):(1,732,414)2,240,142(1,711,689)(2,446,072)(2,730,573)(2,786,151)
Other undisclosed net income (loss) attributable to parent31,050(4,480,284)42,08721,486 (1)
Net loss available to common stockholders, diluted:(1,701,364)(2,240,142)(1,669,602)(2,424,586)(2,730,573)(2,786,152)

Comprehensive Income (USD)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(1,732,414)2,240,142(1,711,689)(2,446,072)(2,730,573)(2,786,151)
Comprehensive income (loss), net of tax, attributable to parent:(1,732,414)2,240,142(1,711,689)(2,446,072)(2,730,573)(2,786,151)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: